医疗保健设备和服务

Search documents
云能国际(01298.HK)7月16日收盘上涨75.71%,成交63.95万港元
Jin Rong Jie· 2025-07-16 08:33
Group 1 - The core viewpoint of the news highlights the significant stock performance of Yuneng International, which saw a 75.71% increase in share price, despite a year-to-date decline of 29.29% [1] - As of December 31, 2024, Yuneng International reported total revenue of 534 million yuan, representing a year-on-year growth of 68.67%, and a net profit attributable to shareholders of 454,700 yuan, with a growth of 109.88% [1] - The company's gross profit margin stands at 5.18%, and its debt-to-asset ratio is 60.43% [1] Group 2 - Currently, there are no institutional investment ratings for Yuneng International [2] - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -3.39 times, with a median of 1.17 times, while Yuneng International's P/E ratio is significantly higher at 392.68 times, ranking 53rd in the industry [2] - Yuneng International is a Bermuda-registered investment holding company, primarily engaged in the distribution and after-sales service of various analytical instruments in China, including chromatography, spectrometers, and electron microscopes [2]
隽泰控股(00630.HK)7月16日收盘上涨11.67%,成交30.26万港元
Sou Hu Cai Jing· 2025-07-16 08:28
Company Overview - JunTai Holdings Limited is a company registered in Bermuda, primarily engaged in the manufacturing and sales of medical equipment, plastic molds, and data media products [2] Financial Performance - As of December 31, 2024, JunTai Holdings reported total revenue of 34.9969 million yuan, a year-on-year increase of 10.07% [1] - The company recorded a net profit attributable to shareholders of -1.1418 million yuan, reflecting a year-on-year growth of 55.21% [1] - The gross profit margin stood at 36.89%, while the debt-to-asset ratio was 62.26% [1] Stock Performance - On July 16, the Hang Seng Index fell by 0.29%, closing at 24,517.76 points [1] - JunTai Holdings' stock closed at 0.335 HKD per share, marking an increase of 11.67% with a trading volume of 901,900 shares and a turnover of 302,600 HKD [1] - Over the past month, JunTai Holdings has seen a cumulative increase of 316.67%, and a year-to-date increase of 150%, outperforming the Hang Seng Index by 22.58% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -3.39 times, with a median of 1.17 times [1] - JunTai Holdings has a P/E ratio of -235.41 times, ranking 56th in the industry [1] - Comparatively, other companies in the sector have P/E ratios such as Star Medical Holdings at 0.26 times, Kingjoy Health at 0.38 times, and others ranging from 1.96 to 5.35 times [1]
中国生物科技服务(08037.HK)7月11日收盘上涨10.77%,成交54.66万港元
Jin Rong Jie· 2025-07-11 08:33
Company Overview - China Biotech Services Holdings Limited (stock code 08037.HK) is listed on the Hong Kong Stock Exchange and is headquartered in Hong Kong [2] - The company aims to create an integrated advanced biotechnology platform for cancer diagnosis and treatment, with business segments including PHC Standard Pathology Laboratory, AMDL Asia Molecular Diagnostics Laboratory, and Vcare Health Management [2] Financial Performance - As of December 31, 2024, the company reported total revenue of 65.2942 million yuan, a year-on-year decrease of 66.74% [1] - The net profit attributable to the parent company was -183 million yuan, a year-on-year decrease of 107.6% [1] - The gross profit margin was -7.01%, and the debt-to-asset ratio was 54.26% [1] Stock Performance - As of July 11, the stock price closed at 0.72 HKD per share, an increase of 10.77% with a trading volume of 765,000 shares and a turnover of 546,600 HKD [1] - Over the past month, the stock has seen a cumulative decline of 14.47%, while it has increased by 27.45% year-to-date, outperforming the Hang Seng Index by 19.78% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry (TTM) is -2.68 times, with a median of 1.17 times [1] - China Biotech Services has a P/E ratio of -3.2 times, ranking 93rd in the industry [1] - Other companies in the industry include Giant Medical Holdings (02393.HK) at 0.28 times, Jingjiu Health (00648.HK) at 0.38 times, Yihui Group (08161.HK) at 1.96 times, Global Medical (02666.HK) at 5.24 times, and Ruici Medical (01526.HK) at 5.4 times [1]
隽泰控股(00630.HK)7月11日收盘上涨9.62%,成交32.15万港元
Jin Rong Jie· 2025-07-11 08:33
Group 1 - The core viewpoint of the article highlights the significant stock performance of JunTai Holdings, with a recent increase of 465.22% over the past month and 116.67% year-to-date, outperforming the Hang Seng Index by 19.78% [1] - As of December 31, 2024, JunTai Holdings reported total revenue of 34.9969 million yuan, a year-on-year increase of 10.07%, and a net profit attributable to shareholders of -1.1418 million yuan, reflecting a year-on-year growth of 55.21% [1] - The company's gross profit margin stands at 36.89%, with a debt-to-asset ratio of 62.26% [1] Group 2 - JunTai Holdings operates primarily in the manufacturing and sales of medical equipment products, plastic molds, and data media products, having expanded its medical equipment business through the acquisition of the Titron Group in October 2011 [2] - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -2.68 times, with a median of 1.17 times, while JunTai Holdings has a P/E ratio of -204.03 times, ranking 56th in the industry [1] - Comparatively, other companies in the industry have P/E ratios such as Giant Medical Holdings at 0.28 times, Jingjiu Health at 0.38 times, Yihui Group at 1.96 times, Global Medical at 5.24 times, and Ruici Medical at 5.4 times [1]
加和国际控股(08513.HK)7月11日收盘上涨11.81%,成交1.4万港元
Sou Hu Cai Jing· 2025-07-11 08:27
Company Overview - 加和国际控股有限公司 is a contract manufacturer based in Singapore, specializing in the production and sale of disposable medical devices and injection-molded plastic components, as well as providing mold-making services [2] - Established in 1981, the company has become a reliable contract manufacturer for major international healthcare and medical device companies [2] - The company's revenue is derived from two main segments: manufacturing and selling disposable medical device components, and providing mold-making services [2] Financial Performance - As of December 31, 2024, 加和国际控股 reported total revenue of 55.6565 million yuan, representing a year-on-year growth of 14.33% [1] - The company recorded a net profit attributable to shareholders of -14.0006 million yuan, showing a year-on-year increase of 61% [1] - The gross profit margin stood at 2.18%, while the debt-to-asset ratio was 75.71% [1] Market Position and Valuation - 加和国际控股's price-to-earnings (P/E) ratio is -6.88, ranking 85th in the industry, compared to the average P/E ratio of -2.68 for the healthcare equipment and services sector [1] - The company has experienced a cumulative decline of 11.19% over the past month and a 28.25% decline year-to-date, underperforming the Hang Seng Index, which has risen by 19.78% [1] - Currently, there are no investment rating recommendations from institutions for 加和国际控股 [1] Industry Context - The healthcare equipment and services industry has an average P/E ratio of -2.68, with a median of 1.17 [1] - Other companies in the industry include 巨星医疗控股 (02393.HK) with a P/E of 0.28, 京玖康疗 (00648.HK) at 0.38, 医汇集团 (08161.HK) at 1.96, 环球医疗 (02666.HK) at 5.24, and 瑞慈医疗 (01526.HK) at 5.4 [1]
雍禾医疗(02279.HK)7月10日收盘上涨13.27%,成交699.39万港元
Sou Hu Cai Jing· 2025-07-10 08:33
Company Overview - Yonghe Medical Group Limited is a medical group providing one-stop hair medical services, focusing on the hair medical service market since 2005 [3] - The company has established a brand matrix including "Yonghe Medical," "Yonghe Hair Transplant," "Shiyunxun," "Yonghe Fazhichu," and "Hafada" [3] - As of June 30, 2023, the company operates 72 hair transplant medical institutions across 68 cities in China [3] - The company has built a professional medical team of over 1,600 members, including more than 300 registered doctors and over 1,000 nurses [3] Financial Performance - For the fiscal year ending December 31, 2024, Yonghe Medical reported total revenue of 1.804 billion yuan, a year-on-year increase of 1.53% [2] - The company recorded a net profit attributable to shareholders of -226 million yuan, showing a significant year-on-year increase of 58.58% [2] - The gross profit margin stands at 60.08%, while the debt-to-asset ratio is 58.65% [2] Stock Performance - Over the past month, Yonghe Medical's stock has increased by 73.45%, and year-to-date, it has risen by 117.78%, outperforming the Hang Seng Index's increase of 19.1% [2] - As of the latest trading session, the stock price was 2.22 HKD per share, reflecting a 13.27% increase with a trading volume of 3.186 million shares and a turnover of 6.9939 million HKD [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -2.53 times, with a median of 0.38 times [3] - Yonghe Medical's P/E ratio is -4.21 times, ranking 89th in the industry [3] - Comparatively, other companies in the sector have P/E ratios such as Giant Star Medical Holdings at 0.28 times, Jingjiu Kangliao at 0.38 times, and others ranging up to 5.35 times [3]
智云健康(09955.HK)7月7日收盘上涨8.26%,成交626.06万港元
Sou Hu Cai Jing· 2025-07-07 08:29
Company Overview - Zhiyun Health (09955.HK) is a leading provider of digital chronic disease management solutions in China, established in 2014 [3] - The company offers a comprehensive range of services including hospital SaaS systems, pharmacy SaaS systems, and advanced internet hospital platforms, covering the entire lifecycle of digital chronic disease management [3] - Zhiyun Health serves over 2,700 hospitals and more than 219,000 pharmacies nationwide, integrating upstream and downstream in the industry chain [3] Financial Performance - As of December 31, 2024, Zhiyun Health reported total revenue of 3.488 billion yuan, a year-on-year decrease of 5.49% [2] - The company experienced a net loss attributable to shareholders of 516 million yuan, a significant decline of 59.85% year-on-year [2] - The gross profit margin stood at 24.7%, with a debt-to-asset ratio of 49.63% [2] Market Performance - On July 7, the stock closed at 1.18 HKD per share, marking an increase of 8.26% with a trading volume of 5.484 million shares and a turnover of 6.2606 million HKD [1] - Over the past month, the stock has seen a cumulative increase of 3.81%, but it has declined by 9.17% year-to-date, underperforming the Hang Seng Index by 19.22% [2] Valuation Metrics - Currently, there are no institutional investment ratings for Zhiyun Health [2] - The company's price-to-earnings (P/E) ratio is -1.26, ranking 99th in the industry, while the average P/E ratio for the healthcare equipment and services sector is -2.82 [2] - Comparatively, other companies in the sector have P/E ratios ranging from 0.29 to 5.2 [2]
巨星医疗控股(02393.HK)7月2日收盘上涨11.5%,成交221.31万港元
Sou Hu Cai Jing· 2025-07-02 08:32
Group 1 - The core business of the company focuses on high-margin medical consumables and equipment, specifically medical imaging products and in vitro diagnostic products [2] - The company has established a strong sales network in China and has gained the trust of international manufacturers such as Fujifilm, Roche Diagnostics, Becton Dickinson, and Thermo Fisher Scientific [2] - The company is the exclusive manufacturer of medical film for Fujifilm in China and one of the largest distributors of Roche's in vitro diagnostic products in the country [2] Group 2 - As of July 2, the company's stock price increased by 11.5% to HKD 0.126 per share, with a trading volume of 16.97 million shares and a turnover of HKD 2.21 million [1] - The company has achieved a cumulative increase of 26.97% in the past month and 82.26% year-to-date, outperforming the Hang Seng Index's 20% increase [1] - Financial data shows that for the year ending December 31, 2024, the company reported total revenue of CNY 2.41 billion, a year-on-year decrease of 17.26%, while net profit attributable to shareholders was CNY 922 million, a year-on-year increase of 6736.05% [1]
天安卓健(00383.HK)7月2日收盘上涨40.74%,成交15.68万港元
Sou Hu Cai Jing· 2025-07-02 08:32
Group 1 - The core viewpoint of the news is that Tian An Medicare is transitioning from an investment holding group to a provider of integrated medical and elderly care services, focusing on expanding its business in China and the Asia-Pacific region [3] - As of July 2, the stock price of Tian An Medicare rose by 40.74% to HKD 1.14 per share, with a trading volume of 165,000 shares and a turnover of HKD 156,800, indicating significant market interest [1] - Financial data shows that for the year ending December 31, 2024, Tian An Medicare achieved total revenue of CNY 1.489 billion, a year-on-year increase of 0.32%, and a net profit attributable to shareholders of CNY 26.6449 million, a substantial increase of 96.03% [1] Group 2 - Currently, there are no institutional investment ratings for Tian An Medicare, and its price-to-earnings (P/E) ratio stands at 30.49, ranking 38th in the healthcare equipment and services industry, which has an average P/E ratio of -3.47 [2] - The company is fully owned by Tongren Medical Industry Group and has several operational institutions, including Nanjing Tongren Hospital and Kunming Tongren Hospital, employing nearly 2,100 staff [3] - The company is actively pursuing various cooperation projects with partners in China and the Asia-Pacific region to diversify its business model and enhance its service offerings [3]
密迪斯肌(08307.HK)6月20日收盘上涨11.84%,成交2万港元
Jin Rong Jie· 2025-06-20 08:31
Company Overview - Medicskin Holdings Limited is a Hong Kong investment holding company primarily providing medical skin care services, founded by Dr. Jiang in 2000 [2] - The company operates two Medicskin centers in Hong Kong, focusing on treating skin diseases and improving appearance [2] - Services offered include treatment for acne, pigmentation, rosacea, eczema, warts, and aesthetic procedures such as skin rejuvenation and contouring [2] Financial Performance - As of September 30, 2024, Medicskin reported total revenue of 20.14 million HKD, a year-on-year decrease of 9.05% [1] - The company recorded a net profit attributable to shareholders of -1.83 million HKD, an increase of 4.24% year-on-year [1] - The gross profit margin stands at 82.16%, with a debt-to-asset ratio of 88.7% [1] Market Position and Valuation - Medicskin's price-to-earnings (P/E) ratio is -20.39, ranking 68th in the healthcare equipment and services industry, which has an average P/E ratio of -20.99 [1] - Other companies in the industry include Giant Medical Holdings (0.33), Kingjoy Health (0.38), Yongsheng Medical (4.39), Global Medical (4.51), and Ruici Medical (5.15) [1] Upcoming Events - The company is scheduled to disclose its annual report for the fiscal year 2024 on June 23, 2025 [3]